A Study to Evaluate the Safety and Efficacy of a Single Dose of RABI-767 in Participants With Acute Pancreatitis

Key Inclusion Criteria:

• Diagnosis of acute pancreatitis

• Predicted severe acute pancreatitis, based on protocol defined criteria

• Lack of clinically meaningful improvement from status at admission, at thediscretion of Investigator, at the time of randomization

• Suitable for EUS-guided study drug administration procedure

• Contrast-enhanced computed tomography (CECT) or magnetic resonance imaging (MRI) ofthe abdomen/pancreas available for the evaluation of exclusion criteria

Key Exclusion Criteria:

• Confirmed severe acute pancreatitis as defined by the Revised Atlanta Classificationof Acute Pancreatitis (ie, Persistent [> 48 hours] organ failure, per ModifiedMarshall Score), prior to randomization

• Anticipated discharge from hospital within 48 hours of randomization

• More than 30% pancreatic necrosis on screening CECT or MRI

• History of previous pancreatic necrosis, including necrosectomy

• History of calcific chronic pancreatitis

• Evidence of cholangitis